---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-137909"
form_type: "8-K"
ticker: "CYCN"
cik: "0001755237"
company_name: "Cyclerion Therapeutics, Inc."
filed_at: "2026-04-01T23:59:59+00:00"
generated_at: "2026-05-15T08:00:13.051853+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Cyclerion to merge with Korsana in reverse merger; $380M PIPE; CVRs for legacy assets

## Summary
- Merger: pre-Merger Korsana stockholders own ~1.5% of combined co (pre-PIPE); Cyclerion shareholders ~98.5%.
- $380M PIPE into Korsana led by institutional investors concurrent with merger.
- Pre-merger Cyclerion shareholders get CVRs for future proceeds from Akebia license, Tisento stock, and other legacy assets.
- Combined co board of 6 all Korsana designees; CEO to be Korsana's president and CEO.
- Merger expected to close Q3 2026; subject to Cyclerion shareholder vote, HSR, Nasdaq approval.

## SEC filing metadata
- accession: 0001193125-26-137909
- form_type: 8-K
- ticker: CYCN
- cik: 0001755237
- company_name: Cyclerion Therapeutics, Inc.
- filed_at: 2026-04-01T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 5.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1755237/000119312526137909/0001193125-26-137909-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1755237/000119312526137909/d128275d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-137909
- JSON: https://secwatch.observer/filing/0001193125-26-137909.json
- Plain text: https://secwatch.observer/filing/0001193125-26-137909.txt

## Key facts
- Material Agreements
  Cyclerion Therapeutics, Inc. entered into Agreement and Plan of Merger and Reorganization with Korsana Biosciences, Inc. (effective 2026-04-01).
  - Action: entry
  - Agreement: merger
  - Counterparty: Korsana Biosciences, Inc.
  - Effective: 2026-04-01
  source text: On April 1, 2026, Cyclerion Therapeutics, Inc., a Massachusetts corporation (“ Cyclerion ”), Cariboos Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of Cyclerion (“ First Merger Sub ”), Cariboos Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of Cyclerion (“ Second Merger Sub ” and, together with First Merger Sub, “ Merger Sub ”), and Korsana Biosciences, Inc., a Delaware corporation (“ Korsana ”), entered into an Agreement and Plan of Merger and Reorganization (the “ Merger Agreement ”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1755237/000119312526137909/0001193125-26-137909-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.